ESR1 and breast carcinoma: Different mechanisms underlying endocrine resistance were identified in metastatic breast cancer (MBC) patients, one of the most recognized mechanisms being the occurrence of activating hotspot mutations in ESR1, ESR1 hotspot mutations are found in around 40% of patients with endocrine-resistant breast cancer [3,4,5,6,7].